Patent Waivers Won’t Impact Big Pharma’s Bottom Line—But Could Slow Covid Vaccine Rollouts Analysts say intellectual property waivers won’t affect vaccine makers Moderna, Pfizer or Novavax—but could paradoxically risk slowing down vaccine production.